Zacks: Analysts Expect BeiGene, Ltd. (NASDAQ:BGNE) to Announce -$4.38 Earnings Per Share

Wall Street analysts expect BeiGene, Ltd. (NASDAQ:BGNEGet Rating) to post ($4.38) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for BeiGene’s earnings, with the highest EPS estimate coming in at ($4.30) and the lowest estimate coming in at ($4.45). BeiGene reported earnings of ($5.23) per share during the same quarter last year, which would suggest a positive year over year growth rate of 16.3%. The business is scheduled to issue its next earnings results on Monday, January 1st.

On average, analysts expect that BeiGene will report full year earnings of ($15.13) per share for the current financial year, with EPS estimates ranging from ($17.44) to ($12.37). For the next financial year, analysts forecast that the firm will report earnings of ($11.85) per share, with EPS estimates ranging from ($16.87) to ($7.49). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow BeiGene.

BeiGene (NASDAQ:BGNEGet Rating) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($4.24) EPS for the quarter, missing the consensus estimate of ($4.12) by ($0.12). The business had revenue of $306.60 million during the quarter, compared to analysts’ expectations of $300.41 million. BeiGene had a negative net margin of 218.25% and a negative return on equity of 40.10%. The business’s revenue for the quarter was down 49.4% on a year-over-year basis.

Several research firms have commented on BGNE. Deutsche Bank Aktiengesellschaft began coverage on BeiGene in a report on Monday, February 7th. They issued a “buy” rating for the company. SVB Leerink cut BeiGene from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $300.00 to $177.00 in a report on Thursday, March 17th. Morgan Stanley boosted their target price on BeiGene from $330.00 to $338.00 and gave the stock an “overweight” rating in a report on Tuesday, April 12th. StockNews.com began coverage on BeiGene in a report on Thursday, March 31st. They set a “sell” rating for the company. Finally, Zacks Investment Research cut BeiGene from a “buy” rating to a “hold” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, BeiGene has a consensus rating of “Buy” and a consensus price target of $281.25.

BGNE traded up $1.39 during midday trading on Friday, hitting $132.87. The company’s stock had a trading volume of 424,882 shares, compared to its average volume of 237,811. The company has a current ratio of 5.05, a quick ratio of 4.61 and a debt-to-equity ratio of 0.03. The firm has a market cap of $13.64 billion, a P/E ratio of -6.61 and a beta of 0.85. The firm has a 50-day moving average price of $175.89 and a two-hundred day moving average price of $241.52. BeiGene has a 52-week low of $120.00 and a 52-week high of $426.56.

In other BeiGene news, COO Xiaobin Wu sold 6,725 shares of the company’s stock in a transaction that occurred on Thursday, May 5th. The stock was sold at an average price of $164.35, for a total value of $1,105,253.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 8.90% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. O Shaughnessy Asset Management LLC lifted its stake in BeiGene by 204.3% during the third quarter. O Shaughnessy Asset Management LLC now owns 70 shares of the company’s stock worth $25,000 after purchasing an additional 47 shares during the last quarter. Pinebridge Investments L.P. bought a new position in BeiGene during the fourth quarter worth $27,000. Koshinski Asset Management Inc. lifted its stake in BeiGene by 139.6% during the first quarter. Koshinski Asset Management Inc. now owns 242 shares of the company’s stock worth $46,000 after purchasing an additional 141 shares during the last quarter. Marshall Wace North America L.P. bought a new position in BeiGene during the first quarter worth $76,000. Finally, Assetmark Inc. lifted its stake in BeiGene by 25.2% in the third quarter. Assetmark Inc. now owns 288 shares of the company’s stock valued at $105,000 after buying an additional 58 shares during the last quarter.

BeiGene Company Profile (Get Rating)

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Recommended Stories

Get a free copy of the Zacks research report on BeiGene (BGNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.